上海市通力律师事务所关于江苏康为世纪生物科技股份有限公司 终止实施 2024 年限制性股票激励计划之法律意见书 致:江苏康为世纪生物科技股份有限公司 SHANGHAI 68 Yin Chena Road Middle hanahai 200120 P R Chin 敬启者: 上海市通力律师事务所(以下简称"本所")受江苏康为世纪生物科技股份有限公司(以 下简称"康为世纪"或"公司")委托,指派本所夏青律师、茹秋乐律师(以下合称"本所律 师")担任公司 2024 年限制性股票激励计划(以下简称"本次股权激励计划")的专项法律顾 问,根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》 (以下简称"《证券法》")、中国证券监督管理委员会(以下简称"中国证监会")发布的《上 市公司股权激励管理办法》(以下简称"《管理办法》")等法律、行政法规和其他规范性文 件(以下简称"法律、法规和规范性文件")以及《江苏康为世纪生物科技股份有限公司章程》 (以下简称"《公司章程》")以及《2024年限制性股票激励计划》(以下简称"《激励计划》") 的有关规定,就公司终止实施 2024 年限制性股票激励 ...

江苏康为世纪生物科技股份有限公司 独立董事关于第二届董事会第十九次会议 相关事项的独立意见 因此，我们一致同意公司董事会根据相关法律法规的规定终止实施 2024 年 限制性股票激励计划的事项，同意将该议案提交股东会审议。 （以下无正文） 江苏康为世纪生物科技股份有限公司 肖 潇、 李映红、 胡宗亥 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易 所科创板股票上市规则》及《江苏康为世纪生物科技股份有限公司章程》（以下 简称"《公司章程》"）等有关规定，我们作为江苏康为世纪生物科技股份有限公 司（以下简称"公司"）独立董事，本着对公司及全体股东负责的态度，基于独立、 客观、审慎的原则，现就公司第二届董事会第十九次会议审议的相关议案发表如 下独立意见： 一、《关于继续使用部分暂时闲置募集资金进行现金管理的议案》的独立意见 经核查，我们认为公司拟在上一次授权期限到期日 2026 年 1 月 11 日起的 12 个月内，继续使用最高额度不超过人民币 1.5 亿元的暂时闲置募集资金进行现 金管理，内容及审议程序符合《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》、《上市公司监管指 ...

江苏康为世纪生物科技股份有限公司 关于继续使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688426 证券简称：康为世纪 公告编号：2026-002 2026 年 1 月 9 日，江苏康为世纪生物科技股份有限公司(以下简称"公司") 召开的第二届董事会审计委员会 2026 年第一次会议、第二届董事会第十九次会 议审议通过了《关于继续使用部分暂时闲置募集资金进行现金管理的议案》，同 意公司在不影响募集资金投资计划正常进行和募集资金安全的前提下，继续使用 最高额度不超过人民币 1.5 亿元的暂时闲置募集资金进行现金管理，用于购买安 全性高、流动性好、保本型理财产品或存款类产品（包括但不限于结构性存款、 定期存款、大额存单等），使用期限在公司董事会审议通过之后，自上一次授权 期限到期日（2026 年 1 月 11 日）起 12 个月内有效，在上述额度和期限内，资 金可循环滚动使用。 公司董事会授权公司管理层在上述额度及决议有效期内行使投资决策权、签 署相关文件等事宜，具体事项 ...

江苏康为世纪生物科技股份有限公司 关于召开2026年第一次临时股东会的通知 证券代码：688426 证券简称：康为世纪 公告编号：2026-004 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 28 日 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 1 月 28 日 14 点 40 分 召开地点：江苏省泰州市医药高新区泽兰路 18 号江苏康为世纪生物科技股 份有限公司 2 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 （七） 涉及公开征集股东投票权 无 至2026 年 1 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东会召开日期：2026年1月28日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 ...

鉴于 2024 年 12 月 4 日公司召开的第二届董事会第十二次会议、第二届监事会第十 一次会议，审议通过了《关于继续使用部分暂时闲置募集资金进行现金管理的议案》， 同意公司在不影响募集资金投资计划正常进行和募集资金安全的前提下，使用最高额度 不超过人民币 3 亿元的暂时闲置募集资金进行现金管理，使用期限于 2026 年 1 月 11 日 到期。 到期后，为提高资金使用效率，增加公司收益，现公司拟在不影响募集资金投资计 划正常进行和募集资金安全的前提下，继续使用额度不超过人民币 1.5 亿元的部分暂时 闲置募集资金进行现金管理，用于购买安全性高、流动性好、保本型理财产品或存款类 产品（包括但不限于结构性存款、定期存款、大额存单等）。使用期限在公司董事会审 议通过之后，自上一次授权期限到期日（2026 年 1 月 11 日）起 12 个月内有效。在上述 额度和期限内，资金可循环滚动使用。 本次会议的召集、召开符合《中华人民共和国公司法》等法律法规以及《公司章程》 的相关规定，会议决议合法、有效。 一、审议通过《关于继续使用部分暂时闲置募集资金进行现金管理的议案》 证券代码：688426 证券简称：康为世纪 公 ...

Group 1 - The core viewpoint of the news is that Kangwei Century has experienced a significant stock price increase, rising 5.33% to 26.48 CNY per share, with a total market capitalization of 2.979 billion CNY and a trading volume of 24.9626 million CNY [1] - Kangwei Century has seen its stock price rise for four consecutive days, with a cumulative increase of 5.63% during this period [1] - The company, established on September 3, 2010, specializes in the research, production, and sales of molecular detection products, with 89.14% of its revenue coming from product sales and 10.86% from services [1] Group 2 - Among the top shareholders, the fund "Yuanxin Yongfeng Medical Health A" has increased its holdings by 277,200 shares, now owning 950,000 shares, which represents 2.5% of the circulating shares [2] - The fund has generated an estimated floating profit of approximately 1.273 million CNY during the four-day stock price increase [2] - The fund has a total asset size of 387 million CNY and has achieved a year-to-date return of 6.77%, ranking 730 out of 8,825 in its category [2]

Group 1 - The core viewpoint of the news is that 康为世纪 (Kangwei Century) has shown significant financial activity, with a notable increase in revenue and a decrease in net profit, indicating a mixed performance in the recent financial period [2][3]. - As of December 31, 康为世纪's stock price increased by 0.13%, with a trading volume of 15.65 million yuan. The financing buy-in amount was 553,800 yuan, while the financing repayment was 1,167,400 yuan, resulting in a net financing buy-in of -613,600 yuan [1]. - The total financing and securities balance for 康为世纪 reached 87.56 million yuan, accounting for 9.56% of its market capitalization, which is above the 70th percentile of the past year [1]. Group 2 - As of September 30, 康为世纪 had 3,905 shareholders, a decrease of 1.11% from the previous period, while the average circulating shares per person increased by 1.13% to 9,729 shares [2]. - For the period from January to September 2025, 康为世纪 reported an operating income of 140 million yuan, representing a year-on-year growth of 42.01%. However, the net profit attributable to the parent company was -76.16 million yuan, showing a year-on-year increase of 20.37% [2]. - Since its A-share listing, 康为世纪 has distributed a total of 48.63 million yuan in dividends [3].

Core Viewpoint - On December 22, a total of 18 listed companies will have their restricted shares unlocked, with a total market value of approximately 102.97 billion yuan [1] Group 1: Unlocking Details - Walton Technology (Stock Code: 000920) will unlock 50.62 million shares from a private placement of A-shares [1] - China Hengtian Group (Stock Code: 600252) will unlock 2.36 million shares from equity incentive restrictions [1] - Huadian Energy (Stock Code: 600726) will unlock 4.73 billion shares from a private placement of A-shares [1] - AVIC Heavy Machinery (Stock Code: 600765) will unlock 2.68 million shares from equity incentive restrictions [1] - Nanjing Port (Stock Code: 002040) will unlock 151,800 shares from equity incentive restrictions [1] - Weichai Power (Stock Code: 000338) will unlock 23.48 million shares from equity incentive restrictions [1] - First Capital Securities (Stock Code: 601136) will unlock 2.25 billion shares from pre-issue share restrictions [1] - Anke Technology (Stock Code: 300370) will unlock 237 million shares from other restrictions [1] - Xinya Process (Stock Code: 002388) will unlock 346,550 shares from equity incentive restrictions [1] - Zhaoyi Innovation (Stock Code: 603986) will unlock 64,600 shares from equity incentive restrictions [1] - Ganli Pharmaceutical (Stock Code: 603087) will unlock 164,530 shares from equity incentive restrictions [1] - Yaxiang Co., Ltd. (Stock Code: 301220) will unlock 33.39 million shares with an extended lock-up period [1] - Mousse Co., Ltd. (Stock Code: 001323) will unlock 300 million shares with an extended lock-up period [1] - Sany Heavy Energy (Stock Code: 688349) will unlock 942 million shares [1] - Southern Power Technology (Stock Code: 688248) will unlock 336 million shares [1] - Jingwei Hengrun (Stock Code: 688326) will unlock 118,400 shares [1] - Kangwei Century (Stock Code: 688426) will unlock 434,200 shares [1] - Yuanjie Technology (Stock Code: 688498) will unlock 23.85 million shares [1]

Core Points - The company will have 434,236 shares listed for circulation on December 22, 2025, as part of its stock option incentive plan [1][2][4] - The total number of shares after the initial public offering (IPO) was 93,161,111, which has since increased to 112,493,716 shares due to stock option exercises and capital increases [2][3] Summary by Sections Listing Details - The type of stock listing is categorized as "other," with a total of 434,236 shares available for subscription through offline methods [1] - The circulation date for the listed shares is set for December 22, 2025 [1] Share Capital Changes - Following the IPO on October 25, 2022, the company had 93,161,111 shares, with 73,115,709 shares under limited circulation and 20,045,402 shares freely tradable [1] - On December 22, 2022, the first exercise of the stock option plan resulted in the issuance of 361,862 shares, raising the total share count to 93,522,973 [2] - A subsequent capital increase on May 16, 2023, led to a further increase in total shares to 112,227,568 [2] - The second exercise of the stock option plan on March 11, 2024, added 266,148 shares, bringing the total to 112,493,716 [3] Lock-up Period and Commitments - The shares being listed are subject to a lock-up period of 36 months from the exercise date, which began on December 22, 2022 [2] - Shareholders involved in the stock option exercise have committed to not reducing their holdings during this period and will adhere to the same reduction regulations as the company's directors and senior management after the lock-up expires [3]

Core Points - The company Jiangsu Kangwei Century Biotechnology Co., Ltd. is set to list 434,236 shares for trading on December 22, 2025, as part of its stock option incentive plan [2][4][11] - The shares being listed are part of the first exercise period of the 2021 stock option incentive plan, with a lock-up period of 36 months from the exercise date [5][7] - The total share capital of the company has increased from 93,161,111 shares at the time of its initial public offering to 112,493,716 shares currently, reflecting various capital increases and stock option exercises [6] Summary of Key Information - The total number of shares to be listed for trading is 434,236 [3][11] - The shares will be available for trading starting December 22, 2025 [4][11] - The shares are part of the stock option plan approved by the China Securities Regulatory Commission, which allowed the company to issue 23,290,278 shares during its IPO [4][5] - The company has undergone several changes in its total share capital since its IPO, including a capital increase through a bonus issue [6] - Shareholders of the newly listed shares have committed to a lock-up period of 36 months and will adhere to the same reduction regulations as the company's directors and senior management after the lock-up period [7][9]